{"count": 5, "results": [{"_id": "36015255", "pmid": 36015255, "pmcid": "PMC9412892", "title": "Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study", "journal": "Pharmaceutics", "authors": ["Elsayed MMA", "Aboelez MO", "Mohamed MS", "Mahmoud RA", "El-Shenawy AA", "Mahmoud EA", "Al-Karmalawy AA", "Santali EY", "Alshehri S", "Elsadek MEM", "El Hamd MA", "Ramadan AEH"], "date": "2022-08-04T00:00:00Z", "doi": "10.3390/pharmaceutics14081629", "meta_date_publication": "2022 Aug 4", "meta_volume": "14", "meta_issue": "8", "meta_pages": "", "score": 50273.68, "text_hl": "The purpose of this study is to make @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@rosuvastatin calcium@@@ (@CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@ROS@@@) and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ (@<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@AT@@@) bilayer tablets to treat coexisting @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ and @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ with a single product. ", "citations": {"NLM": "Elsayed MMA, Aboelez MO, Mohamed MS, Mahmoud RA, El-Shenawy AA, Mahmoud EA, Al-Karmalawy AA, Santali EY, Alshehri S, Elsadek MEM, El Hamd MA, Ramadan AEH. Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study Pharmaceutics. 2022 Aug 4;14(8):. PMID: 36015255", "BibTeX": "@article{36015255, title={Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study}, author={Elsayed MMA and Aboelez MO and Mohamed MS and Mahmoud RA and El-Shenawy AA and Mahmoud EA and Al-Karmalawy AA and Santali EY and Alshehri S and Elsadek MEM and El Hamd MA and Ramadan AEH}, journal={Pharmaceutics}, volume={14}, number={8}}"}}, {"_id": "12808486", "pmid": 12808486, "title": "The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.", "journal": "J Cardiovasc Pharmacol Ther", "authors": ["Rizos E", "Bairaktari E", "Kostoula A", "Hasiotis G", "Achimastos A", "Ganotakis E", "Elisaf M", "Mikhailidis DP"], "date": "2003-06-01T00:00:00Z", "doi": "10.1177/107424840300800206", "meta_date_publication": "2003 Jun", "meta_volume": "8", "meta_issue": "2", "meta_pages": "127-34", "score": 50057.562, "text_hl": "The combination of @CHEMICAL_Nebivolol @CHEMICAL_MESH:D000068577 @@@nebivolol@@@ plus @CHEMICAL_Pravastatin @CHEMICAL_MESH:D017035 @@@pravastatin@@@ is associated with a more beneficial metabolic profile compared to that of @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ plus @CHEMICAL_Pravastatin @CHEMICAL_MESH:D017035 @@@pravastatin@@@ in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@: a pilot study.", "citations": {"NLM": "Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, Elisaf M, Mikhailidis DP. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):127-34. PMID: 12808486", "BibTeX": "@article{12808486, title={The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.}, author={Rizos E and Bairaktari E and Kostoula A and Hasiotis G and Achimastos A and Ganotakis E and Elisaf M and Mikhailidis DP}, journal={J Cardiovasc Pharmacol Ther}, volume={8}, number={2}, pages={127-34}}"}}, {"_id": "16027735", "pmid": 16027735, "title": "beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene.", "journal": "Pharmacogenomics J", "authors": ["Iaccarino G", "Trimarco V", "Lanni F", "Cipolletta E", "Izzo R", "Arcucci O", "De Luca N", "Di Renzo G"], "date": "2005-01-01T00:00:00Z", "doi": "10.1038/sj.tpj.6500324", "meta_date_publication": "2005", "meta_volume": "5", "meta_issue": "5", "meta_pages": "292-7", "score": 50054.875, "text_hl": "In this study, the effects of polymorphisms of the @GENE_IGKV5_2 @GENE_28907;155 @@@beta(2) and beta(3) adrenergic receptor@@@ genes on the occurrence of @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ and @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes mellitus@@@ in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ treated with beta-blockers (@<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ or @CHEMICAL_Metoprolol @CHEMICAL_MESH:D008790 @@@metoprolol@@@) were evaluated. ", "citations": {"NLM": "Iaccarino G, Trimarco V, Lanni F, Cipolletta E, Izzo R, Arcucci O, De Luca N, Di Renzo G. beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene. Pharmacogenomics J. 2005;5(5):292-7. PMID: 16027735", "BibTeX": "@article{16027735, title={beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene.}, author={Iaccarino G and Trimarco V and Lanni F and Cipolletta E and Izzo R and Arcucci O and De Luca N and Di Renzo G}, journal={Pharmacogenomics J}, volume={5}, number={5}, pages={292-7}}"}}, {"_id": "28217401", "pmid": 28217401, "title": "Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol.", "journal": "Metabolomics", "authors": ["Weng L", "Gong Y", "Culver J", "Gardell SJ", "Petucci C", "Morse AM", "Frye RF", "Turner ST", "Chapman A", "Boerwinkle E", "Gums J", "Beitelshees AL", "Borum PR", "Johnson JA", "Garrett TJ", "McIntyre LM", "Cooper-DeHoff RM"], "date": "2016-10-01T00:00:00Z", "doi": "10.1007/s11306-016-1098-2", "meta_date_publication": "2016 Oct", "meta_volume": "12", "meta_issue": "10", "meta_pages": "", "score": 50054.26, "text_hl": "...INTRODUCTION: @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@Atenolol@@@, a commonly prescribed beta blocker for @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, is also associated with adverse cardiometabolic effects such as @DISEASE_Hyperglycemia @DISEASE_MESH:D006943 @@@hyperglycemia@@@ and @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@. ", "citations": {"NLM": "Weng L, Gong Y, Culver J, Gardell SJ, Petucci C, Morse AM, Frye RF, Turner ST, Chapman A, Boerwinkle E, Gums J, Beitelshees AL, Borum PR, Johnson JA, Garrett TJ, McIntyre LM, Cooper-DeHoff RM. Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. Metabolomics. 2016 Oct;12(10):. PMID: 28217401", "BibTeX": "@article{28217401, title={Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol.}, author={Weng L and Gong Y and Culver J and Gardell SJ and Petucci C and Morse AM and Frye RF and Turner ST and Chapman A and Boerwinkle E and Gums J and Beitelshees AL and Borum PR and Johnson JA and Garrett TJ and McIntyre LM and Cooper-DeHoff RM}, journal={Metabolomics}, volume={12}, number={10}}"}}, {"_id": "18174790", "pmid": 18174790, "title": "Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model.", "journal": "Prev Cardiol", "authors": ["Newman J", "Grobman WA", "Greenland P"], "date": "2008-01-01T00:00:00Z", "doi": "10.1111/j.1520-037x.2007.06423.x", "meta_date_publication": "2008 Winter", "meta_volume": "11", "meta_issue": "1", "meta_pages": "36-41", "score": 50038.52, "text_hl": "The initial decision node was to treat or not treat @SPECIES_9606 @@@men@@@ older than 55 years, without @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@CVD@@@, @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, or @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ with a combination of @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@, @CHEMICAL_Captopril @CHEMICAL_MESH:D002216 @@@captopril@@@, @CHEMICAL_Hydrochlorothiazide @CHEMICAL_MESH:D006852 @@@hydrochlorothiazide@@@, and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Newman J, Grobman WA, Greenland P. Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model. Prev Cardiol. 2008 Winter;11(1):36-41. PMID: 18174790", "BibTeX": "@article{18174790, title={Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model.}, author={Newman J and Grobman WA and Greenland P}, journal={Prev Cardiol}, volume={11}, number={1}, pages={36-41}}"}}]}